Keytruda's Exclusivity Timeline
Keytruda (pembrolizumab), Merck's blockbuster PD-1 inhibitor for cancers like melanoma and lung cancer, loses U.S. market exclusivity in 2028. Pediatric exclusivity ends October 31, 2028, opening the door to biosimilars. Multiple companies have filed abbreviated biologics license applications (aBLAs) with the FDA, teeing up launches shortly after.[1][2]
First Biosimilars to Launch
Viatris and Amgen lead the pack with interchangeable biosimilars:
- Viatris/Fujifilm Kyowa Kirin: FDA-approved Oyavasa (pembrolizumab-kjcw) on December 19, 2024, for multiple indications. Launch planned for January 1, 2029, or earlier if litigation resolves favorably. Settlement with Merck allows this timeline.[3][4]
- Amgen: FDA-approved Elgemt (pembrolizumab-fxbj) on February 28, 2025. Settlement permits launch January 1, 2029.[5]
These are poised as the initial entrants, potentially capturing 30-50% market share within years based on historical oncology biosimilar uptake.[1]
Other Major Competitors in the Pipeline
Additional firms are advancing:
- BioCad/Sandoz: Elrexfio biosimilar in Phase 3 trials; European approval targeted for 2025, U.S. post-2028.[6]
- Samsung Bioepis: SB-01ST in FDA review; launch eyed for 2029.[2]
- Celltrion, Biocon, Intas, and Formycon: Late-stage candidates with aBLAs filed or trials ongoing, aiming for 2029-2030 entry.[1][7]
- Chinese players like Innovent and 3SBio: Export-focused biosimilars (e.g., Sintibni) already approved in China, potentially entering U.S./EU markets via partnerships post-exclusivity.[8]
Over 20 biosimilars are in development globally.[1]
How These Stack Up Against Keytruda
Biosimilars match Keytruda's 100 mg/4 mL and 200 mg/4 mL formulations, with comparable efficacy and safety from switching/non-inferiority trials. Interchangeability status (Viatris/Amgen) allows pharmacy substitution without prescriber changes, accelerating adoption. Pricing: Expect 25-35% discounts initially, dropping further with competition, similar to Humira biosimilars.[9][2]
| Competitor | Status | Launch Target | Notes |
|------------|--------|---------------|-------|
| Oyavasa (Viatris) | Approved | Jan 2029 | Interchangeable |
| Elgemt (Amgen) | Approved | Jan 2029 | Interchangeable |
| Samsung Bioepis SB-01ST | Under review | 2029 | High similarity data |
| BioCad/Sandoz | Phase 3 | 2029-2030 | EU-first strategy |
Patent Challenges and Delays
Merck holds patents until 2028-2031 (e.g., formulation, manufacturing). Over 50 lawsuits target these, with settlements (e.g., Amgen, Viatris) setting 2029 launches. Unresolved cases could push others to 2030+. Check DrugPatentWatch.com for latest expiry details and litigation.[10][1]
Market Impact and Patient Options
Post-2028, biosimilars could erode Keytruda's $25B+ annual sales by 50-70% in 2-3 years. Patients gain cheaper access (e.g., $3,000-5,000/month vs. Keytruda's $10,000+), with no proven efficacy gaps in trials. Oncologists report smooth switches in similar cases like Avastin.[9]
Sources
[1]: FDA Biosimilar Pipeline
[2]: Evaluate Pharma Keytruda Report
[3]: FDA Oyavasa Approval
[4]: Viatris Settlement
[5]: FDA Elgemt Approval
[6]: Sandoz Pipeline
[7]: BioPharma Dive Tracker
[8]: FiercePharma China Biosimilars
[9]: IQVIA Biosimilar Uptake
[10]: DrugPatentWatch.com - Keytruda